Protocols

Evidence Limitation Notice: Very limited literature exists on the combined use of Semax, Selank, and DSIP (Delta Sleep-Inducing Peptide) as a therapeutic protocol. The available evidence primarily consists of a single review article from 2026 discussing therapeutic peptides in orthopedic applications, with no specific dosing protocols provided for this combination.

Individual Peptide Information:
Based on the limited available literature, these peptides are typically administered separately rather than as a combination therapy. The review article mentions their potential therapeutic applications but does not provide specific dosing recommendations for combined use.

Research Gaps:

No clinical trials were identified specifically evaluating this three-peptide combination
Dosing protocols for combined administration are not established in peer-reviewed literature
Safety data for this specific combination is not available in the current evidence base
Optimal timing, duration, and administration routes for combined use remain undefined

Clinical Considerations:
The lack of established protocols in the literature suggests this combination represents an investigational approach rather than a standard therapeutic protocol. Any potential use would require careful consideration of individual peptide pharmacokinetics and potential interactions.

Important Medical Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. The limited evidence available does not support specific dosing recommendations for this peptide combination. Any therapeutic use should only be considered under direct medical supervision with appropriate monitoring and informed consent regarding the experimental nature of this approach.

Semax + Selank + DSIP

Member access required